Novavax Announces Entering into a License Agreement with Pfizer
PR Newswire —
Non-exclusive license allows for development by Pfizer to utilize Matrix-M® for up to two disease areas with its products Provides Novavax with an upfront payment of $30 million with the potential for up to another $500 million in development and sales milestones. In addition to milestone...